Inventor
LIANGXING WU
Inventor
US
Overview
Patents· 61 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes22%
Y02ATechnologies for adaptation to climate change3%
C07BGeneral methods of organic chemistry2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
C07KPeptides2%
PatentTitleYear
12,534,463Substituted tricyclic compounds as FGFR inhibitors202612,516,044Heterocyclic compounds as immunomodulators202612,466,822Heterocyclic compounds as immunomodulators202512,466,828Bicyclic amines as CDK2 inhibitors202512,441,731Pyrazolopyrimidine compounds and uses thereof202512,312,331Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors202512,247,038Pyrido[3,2-d]pyrimidine compounds as immunomodulators202512,247,026Heterocyclic compounds as immunomodulators202512,187,725Tricyclic urea compounds as JAK2 V617F inhibitors202512,187,743Heterocyclic compounds as immunomodulators202512,129,267Heteroaryl amide compounds as sting activators202412,060,433CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy202412,030,889Imidazopyridazine and imidazopyridine compounds and uses thereof202411,999,740Fused pyrazine derivatives as A2A / A2B inhibitors202411,981,671Bicyclic pyrazolyl amines as CDK2 inhibitors202411,958,861Spirocyclic lactams as JAK2 V617F inhibitors202411,919,904Sulfonylamide compounds as CDK2 inhibitors202411,919,908Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors202411,912,722Tricyclic heteroaryl compounds as sting activators202411,873,309Heterocyclic compounds as immunomodulators202411,873,304Fused pyrimidine derivatives as A2A/A2B inhibitors202411,866,432Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors202411,866,435Heterocyclic compounds as immunomodulators202411,851,426Bicyclic amines as CDK2 inhibitors202311,840,546Imidazopyridazine compounds and uses thereof202311,840,534Substituted tricyclic compounds as FGFR inhibitors202311,787,793Heterocyclic compounds as immunomodulators202311,780,840Tricyclic urea compounds as JAK2 V617F inhibitors202311,767,323Tricyclic pyridone compounds as JAK2 V617F inhibitors202311,753,413Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors202311,718,605Heterocyclic compounds as immunomodulators202311,713,317Tricyclic heterocyclic compounds as sting activators202311,691,971Naphthyridinone compounds as JAK2 V617F inhibitors202311,673,894Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors202311,673,883Heterocyclic compounds as immunomodulators202311,667,635Bicyclic heterocycles as FGFR4 inhibitors202311,661,422Tricyclic urea compounds as JAK2 V617F inhibitors202311,613,536Heterocyclic compounds as immunomodulators202311,608,337Heterocyclic compounds as immunomodulators202311,596,692PD-L1/STING conjugates and methods of use202311,572,366Heterocyclic compounds as immunomodulators202311,566,026Heterocyclic compounds as immunomodulators202311,535,615Heterocyclic compounds as immunomodulators202211,530,218Spiro compounds as inhibitors of KRAS202211,472,791Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors202211,465,981Heterocyclic compounds as immunomodulators202211,459,329Imidazopyridazine and imidazopyridine compounds and uses thereof202211,447,494Tricyclic amine compounds as CDK2 inhibitors202211,440,914Tricyclic amine compounds as CDK2 inhibitors202211,427,567Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors202211,427,597Heteroaryl amide compounds as sting activators202211,414,433Heterocyclic compounds as immunomodulators202211,407,749Heterocyclic compounds as immunomodulators202211,401,279Pyrido[3,2-d]pyrimidine compounds as immunomodulators202211,401,272Heterocyclic compounds as LSD1 inhibitors202211,384,083Substituted spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'h)-ones as CDK2 inhibitors202211,339,149Heterocyclic compounds as immunomodulators202211,247,992Cyclopropylamines as LSD1 inhibitors202211,173,162Bicyclic heterocycles as FGFR4 inhibitors202111,161,850Fused pyrazine derivatives as A2A / A2B inhibitors202111,155,532Cyclopropylamines as LSD1 inhibitors2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to INCYTE CORP (61)· patent assignee history
2021–2026Based in US· patent location history
2023–2026Patents assigned to INCYTE HOLDINGS CORP (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| INCYTE CORP | 61 | 2021–2026 |
| INCYTE HOLDINGS CORP | 3 | 2023–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 61 | 2021–2026 |